AKTS compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

AKTSAktis Oncology, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

AKTSAktis Oncology, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AKTS3 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.0%▲+4.79%×0.28

May 12 '26—▲+7.99%—

Q1 FY26—▲+8.16%—

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedAKTS realized, solidLLY realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedspan: AKTS 136d · LLY 267dSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

AKTSAktis Oncology, Inc.

15.87▲+6.88%· post 15.87

Mkt cap$874.8MRevenue$3MQ2 FY26Revenue—

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

ClosedNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 6 '26

AKTSAktis Oncology, Inc.

LLYELI Lilly & Co

15.87▲+6.88%post 15.87

Price

1,360.90▼−0.28%post 1,358.90

$874.8M

Mkt cap

$1.2T

Q2 FY26$3M

Revenue

$24.4BQ3 FY26

—

Revenue

$65.2BFY25

AKTS15.87▲+6.88%vsLLY1,360.90▼−0.28%ClosedNov 6 '26